Long-term and developmental outcomes of children with complex congenital heart disease

Matthew D Brown1, Gil Wernovsky, Kathy A Mussatto

  • 1Division of Cardiology, Children's Hospital of Wisconsin, 9000 West Wisconsin Avenue, Milwaukee, WI 53226, USA. mdbrown@chw.org

Clinics in Perinatology
|December 6, 2005
PubMed

Insights

Improved survival in complex congenital heart disease necessitates focus on long-term cardiovascular, neurodevelopmental, and social outcomes to enhance patient quality of life.

Area of Science:

  • Cardiology
  • Pediatric Cardiology
  • Congenital Heart Disease

Background:

  • Advances in medical and surgical treatments have significantly improved short-term survival for complex congenital heart disease.
  • Growing numbers of patients surviving complex congenital heart disease require a deeper understanding of long-term health.
  • Long-term outcomes, including cardiovascular morbidity and neurodevelopmental/social aspects, are critical for this population.

Purpose of the Study:

  • To emphasize the critical need for understanding and addressing long-term outcomes in patients with complex congenital heart disease.
  • To highlight the importance of focusing on cardiovascular morbidity and neurodevelopmental/social development alongside survival.
  • To advocate for continued research and modification of treatment strategies to improve quality of life.

Main Methods:

  • This abstract discusses the conceptual framework and need for further research rather than specific experimental methods.
  • It emphasizes a shift in focus from solely short-term survival to comprehensive long-term patient well-being.
  • The approach involves ongoing study and analysis of patient outcomes.

Main Results:

  • Short-term survival rates for complex congenital heart disease are improving.
  • There is an increasing need to evaluate long-term cardiovascular, neurodevelopmental, and social outcomes.
  • Current understanding necessitates further investigation into these long-term effects.

Conclusions:

  • Continued improvement in survival for complex congenital heart disease demands a parallel focus on long-term quality of life.
  • Understanding long-term outcomes is essential for refining medical and surgical management strategies.
  • Future research should prioritize comprehensive patient well-being, encompassing cardiovascular health and neurodevelopmental/social functioning.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Development of the Heart01:27

Development of the Heart

The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart tube by...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...